Malik Fady Ibraham's Form 4 filing
Cytokinetics Inc (CYTK) · filed Apr 21, 2026
- Accession no.
- 0001061983-26-000043
- Filed
- Apr 21, 2026
- Trade date
- Apr 21, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $229.9K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Malik Fady IbrahamCIK 0001551778 | Officer (EVP Research & Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | Common Stock | MOption exerciseAcquired | +3,500 | $7.80 | +$27,300 | 157,402 | Direct | |
| Apr 21, 2026 | Common Stock | SSaleDisposed | −3,500 | $65.69 | −$229,915 | 153,902 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | Common Stock | MOption exerciseDisposed | −3,500 | $0.00 | $0 | 54,886 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.